Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA Abstract: Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes mellitus. In clinical trials, signi...
Main Authors: | Peggy Soule Odegard, Anthony DeSantis |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-07-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/recent-results-of-exenatide-use-as-adjunctive-therapy-in-the-treatment-a3392 |
Similar Items
-
New indications for exenatide therapy of type 2 diabetes mellitus
by: Olga Konstantinovna Vikulova, et al.
Published: (2010-09-01) -
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
by: Catherine A Schnabel, et al.
Published: (2006-03-01) -
Exenatide Use in the Management of Type 2 Diabetes Mellitus
by: Angelos Kyriacou, et al.
Published: (2010-08-01) -
Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
by: Yuusuke Watanabe, et al.
Published: (2020-03-01) -
Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment
by: Han Liu, et al.
Published: (2022-06-01)